Cite
MLA Citation
Julie Dubourg et al.. “Long‐term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52‐week, open‐label, multicentre phase 3 trial.” Diabetes, obesity & metabolism, vol. 24, no. 4, 2022, pp. 609–619. http://access.bl.uk/ark:/81055/vdc_100152644657.0x000022